Galmed Pharmaceuticals

Focus: Galmed Pharmaceuticals is an Israeli-based biotech focused on oral liver therapies, primarily developing Aramchol for hepatic and metabolic diseases. The company operates as a clinical-stage development organization with a concentrated pipeline in liver disease indications.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Galmed Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Galmed Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Aramchol

Healthy

Phase 1

Clinical Trials (1)

NCT00776841A Phase 1 Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers

Phase 1

Help build intelligence for Galmed Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Lead program (Aramchol free acid) in Phase 3 for NASH, a high-unmet-need indication with significant commercial potential
Diversified pipeline with 16 active trials across multiple liver disease indications including NASH, NAFLD, PSC, and gallstones
Israel-based location offers exposure to innovative biotech ecosystem and potentially favorable tax/incentive environment for R&D roles

Watch Out For

Zero active job openings reported—company appears to be in optimization phase with limited near-term hiring momentum
All financial data unavailable (funding, revenue, cash position, headcount)—raises questions about funding sustainability and burn rate
Early-stage pipeline dominance (10 Phase 1 programs) means limited near-term catalysts; Phase 3 program (Aramchol NASH) is sole late-stage asset

Generated by Claude from Galmed Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Aramchol

Healthy

Phase 1

Clinical Trials (1)

NCT03760848Study of Potential for Drug Interactions Mediated by CYP3A4 Inhibition With Aramchol in Healthy Volunteers

Phase 1

Aramchol

Healthy

Phase 1

Clinical Trials (1)

NCT03774173Comparison of Aramchol Concentrations With Once or Twice Daily Dosing

Phase 1

Aramchol meglumine

Healthy

Phase 1

Clinical Trials (1)

NCT06502561Comparing The PK Of Aramchol Meglumine Granules To Aramchol Free Acid Tablets

Phase 1

Aramchol

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT02803996Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol Administered Under Fed Conditions in Healthy Chinese Volunteers

Phase 1

Aramchol

Healthy Volunteers

Phase 1

Clinical Trials (1)

NCT02374437Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol and Food Effect in Healthy Volunteers

Phase 1

amilo-5MER

Inflammatory Disease

Phase 1

Clinical Trials (1)

NCT05857215A First-in-Human Study of Single and Multiple Doses of Amilo-5MER in Healthy Subjects

Phase 1

Aramchol

NASH

Phase 1

Clinical Trials (1)

NCT05874336An Open-Label, Two-Part Study Designed to Assess the Absolute Bioavailability and Mass Balance of Aramchol

Phase 1

Aramchol free acid tablet 600mg, single dose

Hepatic Impairment

Phase 1

Clinical Trials (1)

NCT04480827Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment

Phase 1

Aramchol

Healthy

Phase 1

Clinical Trials (1)

NCT07251712Single and Multiple Dose Pharmacokinetics (PK) of Aramchol From an Aramchol Meglumine Tablet

Phase 1

mFOLFOX6 + BIBF 1120

Colorectal Cancer

Phase 2

Clinical Trials (1)

NCT01362361TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)

Phase 2

Aramchol meglumine

Primary Sclerosing Cholangitis

Phase 2

Clinical Trials (1)

NCT06095986A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis

Phase 2

Aramchol

Non-Alcoholic Fatty Liver Disease

Phase 2

Clinical Trials (1)

NCT01094158Study of Aramchol in Patients With Fatty Liver Disease or Nonalcoholic Steatohepatitis